Market closed

Fate Therapeutics/$FATE

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Fate Therapeutics

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Ticker

$FATE

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Diego, United States

Employees

181

Website

www.fatetherapeutics.com

FATE Metrics

BasicAdvanced

$143M

-

-$1.64

1.88 -

Price and volume

Market cap

$143M

Beta

1.88

52-week high

$8.83

52-week low

$1.04

Average daily volume

3.4M

Financial strength

Current ratio

8.292

Quick ratio

8.096

Long term debt to equity

25.415

Total debt to equity

27.317

Management effectiveness

Return on assets (TTM)

-22.11%

Return on equity (TTM)

-46.59%

Valuation

Price to revenue (TTM)

10.162

Price to book

0.39

Price to tangible book (TTM)

0.39

Price to free cash flow (TTM)

-1.031

Growth

Revenue change (TTM)

-87.34%

Earnings per share change (TTM)

-7.08%

3-year revenue growth (CAGR)

-37.35%

3-year earnings per share growth (CAGR)

-8.22%

What the Analysts think about FATE

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Fate Therapeutics stock.

FATE Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

FATE Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

FATE News

AllArticlesVideos

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire·2 weeks ago

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

GlobeNewsWire·1 month ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $FATE

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Fate Therapeutics stock?

Fate Therapeutics (FATE) has a market cap of $143M as of January 15, 2025.

What is the P/E ratio for Fate Therapeutics stock?

The price to earnings (P/E) ratio for Fate Therapeutics (FATE) stock is 0 as of January 15, 2025.

Does Fate Therapeutics stock pay dividends?

No, Fate Therapeutics (FATE) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Fate Therapeutics dividend payment date?

Fate Therapeutics (FATE) stock does not pay dividends to its shareholders.

What is the beta indicator for Fate Therapeutics?

Fate Therapeutics (FATE) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.